---

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C.
20549

FORM 10-Q

(Mark One)

[ x ] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2009

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to
___________________

Commission file number _______________________

PURE PHARMACEUTICALS CORPORATION(Exact name of Registrant as Specified in Its Charter)

|NEVADA                                           | 45-0476087                       
|------------------------------------------------ | ---------------------------------
|(State or Other Jurisdiction of Incorporation or | (IRS Employer Identification No.)
|Organization)                                    |                                  
|                                                 |                                  
|                                                 |                                  
|P.O. BOX 55, 1594 STONE MILL PARK,               | 14415                            
|BELLONA, NY                                      |                                  
|(Address of Principal Executive Offices)         | (Zip Code)                       

(315) 849-2822(Registrants Telephone Number,
Including Area Code)

_________________________________________________________________(Former
Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant: (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.Yes [ x ] No [ ]

Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, or a non-accelerated filer. See
definition of accelerated filer and large accelerated filer in Rule 12b-2 of
the exchange Act. (Check One)

|Large Accelerated Filer [ ] | Accelerated Filer [ ] | Non-Accelerated Filer [ ]
|--------------------------- | --------------------- | -------------------------

---

Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).Yes [ x ] No [ ]

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS
DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all
documents and reports required to be filed by Sections 12, 13 or 15(d) of the
Securities Exchange Act of 1934 subsequent to the distribution of securities
under a plan confirmed by a court.Yes [ ] No [ ]

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the
issuers classes of common stock, as of the latest practicable date.

*Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of large accelerated filer,
accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):

|Large accelerated filer [ ]                   | Accelerated filer [ ]          
|--------------------------------------------- | -------------------------------
|                                              |                                
|Non-accelerated filer [ ]                     | Smaller reporting company [ x ]
|(Do not check if a smaller reporting company) |                                

---

PART 1 FINANCIAL INFORMATION

Item 1. Financial Statements.

PURE PHARMACEUTICAL CORPORATION (A Development Stage
Company)

FINANCIAL STATEMENTS

MARCH 31, 2009

---

|PURE PHARMACEUTICAL CORPORATION
|-------------------------------
|(A Development Stage Company)  
|                               
|BALANCE SHEETS                 
|                               
|(Unaudited)                    

|                                                           |  |                |   |  | September 30, |  
|---------------------------------------------------------- |  | -------------- | - |  | ------------- | -
|                                                           |  | March 31, 2009 |   |  | 2008          |  
|                                                           |  | -
      $ -    |   |  | -
      $ -   |  
|                                                           |  |                |   |  |               |  
|ASSETS                                                     |  |                |   |  |               |  
|Current                                                    |  |                |   |  |               |  
|Cash                                                       |  | 859            |   |  | 12,459        |  
|                                                           |  | 859            |   |  | 12,459        |  
|                                                           |  |                |   |  |               |  
|LIABILITIES                                                |  |                |   |  |               |  
|Current                                                    |  |                |   |  |               |  
|Accounts payable
      and accrued liabilities             |  | 18,734         |   |  | 46,213        |  
|                                                           |  |                |   |  |               |  
|Long term loan                                             |  | 57,024         |   |  | 40,000        |  
|                                                           |  | 75,758         |   |  | 86,213        |  
|                                                           |  |                |   |  |               |  
|STOCKHOLDERS EQUITY                                       |  |                |   |  |               |  
|Authorized:                                                |  |                |   |  |               |  
|100,000,000 common shares with a par value
      of $0.001 |  |                |   |  |               |  
|Issued and Outstanding:                                    |  |                |   |  |               |  
|12,600,000 common shares                                   |  |                |   |  |               |  
|(September 30, 2008  12,600,000)                          |  | 12,600         |   |  | 12,600        |  
|Additional paid up capital                                 |  | 166,600        |   |  | 161,800       |  
|Accumulated comprehensive loss                             |  | 3,605          |   |  | 271           |  
|Deficit accumulated during the development stage           |  | (257,704       | ) |  | (248,425      | )
|                                                           |  | (74,899        | ) |  | (73,754       | )
|                                                           |  | 859            |   |  | 12,459        |  

 See Accompanying Note 

---

|PURE PHARMACEUTICAL CORPORATION
|-------------------------------
|(A Development Stage Company)  
|                               
|STATEMENTS OF OPERATIONS       
|                               
|(Unaudited)                    

|                              |  |            |   |  |              |   |  |            |   |  |            |   |  | Cumulative     |  
|----------------------------- |  | ---------- | - |  | ------------ | - |  | ---------- | - |  | ---------- | - |  | -------------- | -
|                              |  |            |   |  |              |   |  |            |   |  |            |   |  | from           |  
|                              |  | Three      |   |  | Three months |   |  |            |   |  |            |   |  | September 24,  |  
|                              |  | months     |   |  | ended March  |   |  | Six months |   |  | Six months |   |  | 2004           |  
|                              |  | ended      |   |  | 31, 2008     |   |  | ended      |   |  | ended      |   |  | (Inception) to |  
|                              |  | March 31,  |   |  | - $ -        |   |  | March 31,  |   |  | March 31,  |   |  | March 31,      |  
|                              |  | 2009       |   |  |              |   |  | 2009       |   |  | 2008       |   |  | 2009           |  
|                              |  | - $ -      |   |  |              |   |  | - $ -      |   |  | - $ -      |   |  | - $ -          |  
|                              |  |            |   |  |              |   |  |            |   |  |            |   |  |                |  
|Revenue                       |  | 4,310      |   |  | -            |   |  | 8,310      |   |  | -          |   |  | 20,398         |  
|Cost of
      sales           |  | -          |   |  | -            |   |  | -          |   |  | -          |   |  | 9,670          |  
|                              |  | 4,310      |   |  | -            |   |  | 8,310      |   |  | -          |   |  | 10,728         |  
|                              |  |            |   |  |              |   |  |            |   |  |            |   |  |                |  
|Expenses                      |  |            |   |  |              |   |  |            |   |  |            |   |  |                |  
|Financing fees                |  | -          |   |  | -            |   |  | -          |   |  | -          |   |  | 5,600          |  
|General and                   |  |            |   |  |              |   |  |            |   |  |            |   |  |                |  
|administrative                |  | 9,446      |   |  | 28,579       |   |  | 14,789     |   |  | 36,996     |   |  | 254,902        |  
|Interest expense              |  | 2,000      |   |  | -            |   |  | 2,800      |   |  | -          |   |  | 2,800          |  
|Write-down of
      inventory |  | -          |   |  | -            |   |  | -          |   |  | -          |   |  | 5,130          |  
|                              |  | 11,446     |   |  | 28,579       |   |  | 17,589     |   |  | 36,996     |   |  | 268,432        |  
|Net loss                      |  | (7,136     | ) |  | (28,579      | ) |  | (9,279     | ) |  | (36,996    | ) |  | (257,704       | )
|                              |  |            |   |  |              |   |  |            |   |  |            |   |  |                |  
|Loss per share  basic        |  |            |   |  |              |   |  |            |   |  |            |   |  |                |  
|and diluted                   |  | (0.00      | ) |  | (0.00        | ) |  | (0.00      | ) |  | (0.00      | ) |  |                |  
|                              |  |            |   |  |              |   |  |            |   |  |            |   |  |                |  
|Weighted average              |  |            |   |  |              |   |  |            |   |  |            |   |  |                |  
|number of common              |  |            |   |  |              |   |  |            |   |  |            |   |  |                |  
|shares outstanding           |  |            |   |  |              |   |  |            |   |  |            |   |  |                |  
|basic and
      diluted       |  | 12,600,000 |   |  | 12,600,000   |   |  | 12,600,000 |   |  | 12,600,000 |   |  |                |  

 See Accompanying Note 

---

|PURE PHARMACEUTICAL CORPORATION
|-------------------------------
|(A Development Stage Company)  
|                               
|STATEMENTS OF CASH FLOWS       
|                               
|(Unaudited)                    

|                                                   |  |            |   |  |            |   |  | Cumulative     |  
|-------------------------------------------------- |  | ---------- | - |  | ---------- | - |  | -------------- | -
|                                                   |  |            |   |  |            |   |  | from           |  
|                                                   |  | Six months |   |  | Six months |   |  | September 24,  |  
|                                                   |  | ended      |   |  | ended      |   |  | 2004           |  
|                                                   |  | March 31,  |   |  | March 31,  |   |  | (Inception) to |  
|                                                   |  | 2009       |   |  | 2008       |   |  | March 31,      |  
|                                                   |  | - $ -      |   |  | - $ -      |   |  | 2009           |  
|                                                   |  |            |   |  |            |   |  | - $ -          |  
|                                                   |  |            |   |  |            |   |  |                |  
|Cash Flows From Operating Activities               |  |            |   |  |            |   |  |                |  
|Net loss                                           |  | (9,279     | ) |  | (36,996    | ) |  | (257,704       | )
|Non-cash items:                                    |  |            |   |  |            |   |  |                |  
|Donated capital                                    |  | 4,800      |   |  | 4,800      |   |  | 43,200         |  
|Accrued interest on long term loan                 |  | 2,800      |   |  | -          |   |  | 2,800          |  
|Write off in inventory                             |  | -          |   |  | -          |   |  | 5,130          |  
|Change in non-cash working capital
      balances: |  |            |   |  |            |   |  |                |  
|Inventory                                          |  | -          |   |  | -          |   |  | (5,130         | )
|Accounts payable                                   |  | (27,479    | ) |  | 19,791     |   |  | 18,734         |  
|Net cash used in
      operations                  |  | (29,158    | ) |  | (12,405    | ) |  | (192,970       | )
|                                                   |  |            |   |  |            |   |  |                |  
|Cash Flows From Financing Activities               |  |            |   |  |            |   |  |                |  
|Capital stock issued                               |  | -          |   |  | -          |   |  | 136,000        |  
|Long term debt                                     |  | 14,224     |   |  |            |   |  | 54,224         |  
|Net cash provided by financing activities          |  | 14,224     |   |  | -          |   |  | 190,224        |  
|                                                   |  |            |   |  |            |   |  |                |  
|Effect of exchange rate changes                    |  | 3,334      |   |  | -          |   |  | 3,605          |  
|                                                   |  |            |   |  |            |   |  |                |  
|Increase (Decrease) In Cash                        |  | (11,600    | ) |  | (12,405    | ) |  | 859            |  
|                                                   |  |            |   |  |            |   |  |                |  
|Cash, beginning                                    |  | 12,459     |   |  | 28,906     |   |  | -              |  
|Cash,
      ending                                 |  | 859        |   |  | 16,501     |   |  | 859            |  
|                                                   |  |            |   |  |            |   |  |                |  
|Supplementary Cash Flow Information:               |  |            |   |  |            |   |  |                |  
|Cash paid for:                                     |  |            |   |  |            |   |  |                |  
|Interest                                           |  | -          |   |  | -          |   |  | -              |  
|Income taxes                                       |  | -          |   |  | -          |   |  | -              |  

- See Accompanying Note -

---

|PURE PHARMACEUTICAL CORPORATION 
|--------------------------------
|(A Development Stage Company)   
|                                
|NOTE TO THE FINANCIAL STATEMENTS
|                                
|MARCH 31, 2009                  
|(Unaudited)                     

|1. | BASIS OF PRESENTATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|-- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
|   | Unaudited Interim Consolidated Financial
      Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
|   | The accompanying unaudited interim financial statements
      have been prepared in accordance with generally accepted accounting
      principles for interim financial information and in accordance with the
      rules and regulations of the Securities and Exchange Commission. They may
      not include all information and footnotes required by generally accepted
      accounting principles for complete financial statements. However, except
      as disclosed herein, there has been no material changes in the information
      disclosed in the notes to the financial statements for the year ended
      September 30, 2008, included in the Companys Form 10-KSB filed with the
      Securities and Exchange Commission. The unaudited interim financial
      statements should be read in conjunction with those financial statements
      included in the Form 10-KSB. In the opinion of Management, all adjustments
      considered necessary for a fair presentation, consisting solely of normal
      recurring adjustments, have been made. Operating results for the six
      months ended March 31, 2009 are not necessarily indicative of the results
      that may be expected for the year ending September 30,
  2009.

Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations.

Forward Looking Statements

In addition to historical information, the following discussion
and other parts of this document may contain forward-looking statements. These
statements relate to future events or our future financial performance. In some
cases, you can identify forward-looking statements by terminology such as "may,"
"will," "should," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential," or "continue," the negative of such terms or other
comparable terminology. These statements are only predictions. The events
described in forward looking statements we make in this Form 10-Q may not occur.
Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results, levels of
activity, performance or achievements. We caution you that these statements are
not guarantees of future performance or events and are subject to a number of
uncertainties risks and other influences, many of which are beyond our control
that may influence the accuracy of the statements and the projections upon which
the statements are based. Moreover, neither we nor any other person assume
responsibility for the accuracy and completeness of the forward-looking
statements. Except as may be required by law, we undertake no obligation to
publicly update any of the forward-looking statements after the date of this
report to conform such statements to actual results or to changes in our
expectations.

Actual results could differ materially from those anticipated
by such forward-looking statements. The following discussion should be read in
conjunction with the financial statements as well as other financial information
appearing elsewhere in this document. Readers are also urged to carefully review
and consider the various disclosures made by us which attempt to advise
interested parties of the factors which affect our business.

---

Our Business

The Company was formed in order to seek business opportunities in the area of expertise of the Company's principal stockholder, Mr. Roger Gordon, being biological and/or medical products for animal use. The Company principally operated in the field
of generic animal health and nutrition products, specifically medicated feed additives (MFAs). MFAs are used preventively and therapeutically in animal feed to prevent disease and foster growth in livestock. In North America, 90% of all feed to
animals contain MFAs, but has been on the decrease in the last five years. Our intended customers operate in the poultry, swine and cattle markets. The Company has historically focused its efforts on generic MFAs, as they have come off patent,
therefore making them more economical to register with requisite regulators in the United States and Canada, with a view to bringing the products to market.

The Company continued to market a related-party owned MFA, Oxytetracycline, and are in the exploratory phase of identifying generic MFAs that it intended to test and register with regulatory authorities with a view to being granted a DIN or similar
authorization to market such MFAs in North America (henceforth, the identification process). As market dynamics have undergone significant systemic changes over the past three years with the emergence of avian flu and the attendant fall in poultry
consumption worldwide, management has had to conduct the identification process with due deliberation. Furthermore, with the prices of feed, particularly maize, at record high prices, out intended customers have been hesitant to add to their
expenses.

The Company's activities to date have been primarily organizational in nature and as a result the Company must be considered to be in its developmental stage. The Company relies solely on the efforts of its management and director and has no
employees, owns few business assets, technology or real estate and since inception has been primarily involved in developing its business plan, preliminarily identifying generic MFAs for registration, and raising initial capital.

Management previously determined to refocus, assess and identify alternative business strategies due to prolonged high prices of maize and other inputs and other general economic conditions affecting the business of the Company.

Recent Developments

Sales have decreased year over year due to the increasing prices of maize. As a result of the prolonged high prices of inputs and other general conditions affecting the business of the Company, management determined, in the prior quarter, to
refocus, assess and identify alternative business strategies. In July 2008, the Company was quoted on the OTC Bulletin Board under the symbol PPMA.

Results of Operations

Results of Operations for the Period ended March 31, 2009

The company was able to sell the remainder of its Oxytetracline MFA and earned $5,000 Canadian Dollars from its sale in the 3 months ended March 31, 2009. We incurred operating expenses in the amount of $11,446 for the three months ended
March 31, 2009. Our net loss for the three months ended was $7,136. As at March 31, 2009 we had cash of $859. The companys losses stem from the payment of professional fees.

Sales and marketing of the companys Oxytetracyline and
  the process of the company pursuing opportunities in the generic MFAs areas
  continue to be very difficult this quarter. Though we recorded revenue, we do
  not anticipate importing more in the next six months going forward as the manufacturer
  in the Peoples Republic of China is idling production until the overall
  economic situation improves. Due to

---

acute fluctuations in the price of key ingredients; corn and
soybeans; the ability for producers to manage price pressure is severely
challenged. Corn prices see-sawed and surged 3 to-5 fold in the last 24 months
to $750 USD per bushel mid 2008 and plummeted to the $370 per bushel by year
end1. Farmers and buyers are taking a wait and see approach and
farmers in particular are not selling their crops and holding out for better
prices. Management and analysts believe the competition for corn, once viewed as
a commodity and now viewed as a matter of national security for countries, is
here to stay. Though prices have dropped in the last six months of 2009, the
price is still double that of three years ago in January 2006. The use of corn
for the production of ethanol and the agricultural polices of leading petroleum
usage countries continue to exert price and demand pressures on the
market2. Also confounding the problem is worldwide health concerns
and reaction to animal borne disease transmission to humans.

Due to the prolonged high prices of inputs, this upward cycle
  has lasted for 3 years, and general economic conditions which are affecting
  the business of the company; management has determined to refocus, assess, and
  identify alternative business strategies.

Liquidity and Capital Resources

Our cash reserves of $859 as at March 31, 2009 ($12,459 as at
September 30, 2008) are not sufficient to meet our funding needs beyond the next
nine-month period. To this effect, the company will need to seek additional
funding in the near future. We currently do not have a specific plan for
obtaining such funding, however, we anticipate that any additional funding will
be in the form of equity financing from the sale of our common stock and/or
loans (interest or convertible). We currently do not have any arrangements in
place for any future equity financing. We may also seek to obtain short-term
loans from our directors, although no such arrangements have as yet been made.
There can be no assurance that we will be able to raise sufficient funding from
the sale of our common stock or through director loans to meet our funding needs
after the next nine months.

The Independent Auditor's Report to our audited financial
statements for the period ended September 30, 2008 indicated that there are a
number of factors that raise substantial doubt about our ability to continue as
a going concern. Such factors identified in the report include that we need to
generate profitable operations and are in need of obtaining adequate financing.
For these and other related reasons our auditors believe that there is
substantial doubt that we will be able to continue as a going concern.

Comparison of Interim Financial Results

As at March 31, 2009, accounts payable balance is $18,734
compared to $46,213 as at September 30, 2008. Our long term loan payable balance
is $57,024 compared to $40,000 as at September 30, 2008.

Sales have decreased year over year due to the increasing and
volatility prices of maize

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements
  that have or are reasonably likely to have a current or future effect on the
  small business issuer's financial condition, changes in financial condition,
  revenues or expenses, results of operations, liquidity, capital expenditures
  or capital resources that are material to investors.

Item 3. Quantitative and Qualitative Disclosures About Market
  Risk.

Not applicable.

|________________________________
|--------------------------------
|1                               
|2                               

---

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures. The
Company's Management under the supervision and with the participation of the
Principal Executive Officer and the Principal Financial Officer are responsible
for establishing and maintaining "disclosure controls and procedures" (as
defined in the Exchange Act) for the Company. Based on their evaluation of the
Company's disclosure controls and procedures as of March 31, 2009, the Company's
Management has concluded that the Company's disclosure controls and procedures
were effective to ensure that the information required to be disclosed by the
Company under the Exchange Act was recorded, processed, summarized and reported
within the time periods specified in the Exchange Act and accumulated and
communicated to the Company's Management, including the Principal Executive
Officer and the Principal Financial Officer, to allow timely decisions regarding
required disclosure.

Changes in Internal Control over Financial Reporting.During the fiscal quarter ending March 31, 2009, there were no changes in
the Company's internal control over financial reporting during the period
covered by this report that have materially affected, or are reasonably likely
to materially affect, the Company's internal control over financial
reporting.

Limitations on the Effectiveness of Controls.A control
system, no matter how well conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the control system are met.
Because of the inherent limitations in all control systems, no evaluation of
controls can provide absolute assurance that all control issues, if any, within
a company have been detected. The Company's disclosure controls and procedures
are designed to provide reasonable assurance of achieving their objectives, and
the Principal Executive Officer and the Principal Financial Officer have
concluded that these controls and procedures are effective at the "reasonable
assurance" level.

Item 4T. Controls and Procedures.

The Company's management is responsible for establishing and
maintaining adequate internal control over financial reporting. Our internal
control over financial reporting is designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted
accounting principles.

Our internal control over financial reporting includes those
policies and procedures that:

- Pertain to the maintenance of records that, in reasonable detail,
  accurately and fairly reflect the transactions and dispositions of the assets
  of the Company;
- Provide reasonable assurance that transactions are recorded as necessary to
  permit preparation of financial statements in accordance with generally
  accepted accounting principles, and that receipts and expenditures are being
  made only in accordance with authorizations of management and the director;
  and
- Provide reasonable assurance regarding prevention or timely detection of
  unauthorized acquisition, use or disposition of assets that could have a
  material effect on the financial statements.

As required by Rule 13a-15 and 15d-15 under the Securities and
Exchange Act of 1934, Management assessed the effectiveness of the Companys
internal control over financial reporting as of March 31, 2009.

---

Based on this assessment, the Company's management has
concluded that the Company maintained effective internal control over financial
reporting as of March 31, 2009, the end of the period covered by this quarterly
report.

This quarterly report does not include an attestation report of
the company's registered public accounting firm regarding internal control over
financial reporting. Management's report was not subject to attestation by the
company's registered public accounting firm pursuant to temporary rules of the
Securities and Exchange Commission ("SEC") that permit the Company to provide
only management's report in this quarterly report.

Changes in Internal Control over Financial Reporting.Management has evaluated whether any changes in our internal control over
financial reporting that occurred during our last fiscal quarter have materially
effected, or reasonably likely to materially effect our internal control over
financial reporting. Based on the evaluation we conducted, management has
concluded that during the fiscal quarter ending March 31, 2009, there were no
changes in the Company's internal control over financial reporting during the
period covered by this report that have materially affected, or are reasonably
likely to materially affect, the Company's internal control over financial
reporting.

A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the
control system are met. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues, if any, within a company have been detected. The Company's
disclosure controls and procedures are designed to provide reasonable assurance
of achieving their objectives, and the Principal Executive Officer and the
Principal Financial Officer have concluded that these controls and procedures
are effective at the "reasonable assurance" level.

PART II  OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently a party to any legal proceedings.

Item 1A. Risk Factors.

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of
Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security
Holders.

No matters have been submitted to our security holders for a
vote, through the solicitation of proxies or otherwise, during the quarterly
period ended March 31, 2009.

Item 5. Other Information.

None.

---

Item 6. Exhibits.

|31.1 | Certification
        of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley
        Act of 2002.
|---- | -----------------------------------------------------------------------------------------------------------------------
|     |                                                                                                                        
|31.2 | Certification
        of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley
        Act of 2002.
|     |                                                                                                                        
|32.1 | Certification
        of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley
        Act of 2002.
|     |                                                                                                                        
|32.2 | Certification
        of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley
        Act of 2002.

---

SIGNATURES

In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

|                   | PURE PHARMACEUTICALS CORPORATION                         
|------------------ | ---------------------------------------------------------
|                   | (Registrant)                                             
|                   |                                                          
|                   |                                                          
|Date: May 19, 2009 | By: /s/ Roger Gordon                                     
|                   | Roger Gordon                                             
|                   | President, Principal Executive Officer and
      Director
|                   |                                                          
|                   |                                                          
|                   |                                                          
|Date: May 19, 2009 | By: /s/ Charlie Lee                                      
|                   | Charlie Lee                                              
|                   | Secretary and Principal Accounting Officer               

---